Aptinyx Inc. is a biopharmaceutical company in the clinical development stage, focused on identifying, advancing, and commercializing innovative, proprietary, synthetic small-molecule therapies for neurological and central nervous system disorders. Its primary drug candidate, NYX-2925, is currently in Phase II clinical trials for addressing painful diabetic peripheral neuropathy, and also in Phase IIb evaluation for fibromyalgia. Additionally, the company is developing NYX-783, an N-methyl-D-aspartate receptor (NMDAr) modulator, which is undergoing Phase IIb clinical trials for post-traumatic stress disorder (PTSD). Another NMDAr modulator, NYX-458, is in Phase II clinical study, targeting cognitive impairment related to Parkinson's disease. Aptinyx Inc. also holds a research collaboration agreement with Allergan plc. The company was founded in 2015 and is based in Evanston, Illinois.